Data Supplement
- Supplemental Data -
Supplemental Figure 1 - Effect of specific CYP inhibitors on M0 depletion in HLM incubations containing imrecoxib, NADPH, and individual inhibitor
Supplemental Figure 2 - Mean plasma concentration-time curves for M2 after a single intravenous administration of 5 mg/kg imrecoxib, M1, and M-CHO, respectively to rats (n = 5/group)
Supplemental Figure 3 - Incubations of M1 (10 μM) in NADPH- or NAD-supplemented human renal homogenate (HRH, unknown concentration) (A), and in freshly prepared rat renal and liver homogenate (unknown concentration) for 0.33, 0.5, 1.0, 2.0, 4.0, 6.0 h (B)
Supplemental Table 1 - Characterization of imrecoxib metabolites in humans using UPLC/Q-TOF MS
Supplemental Table 2 - Pharmacokinetic parameters of imrecoxib and its two active metabolites after an oral administration of 100 mg imrecoxib to healthy volunteers (n = 10)